TY - JOUR
T1 - The key role of microRNA-766 in the cancer development
AU - Gupta, Jitendra
AU - Kareem Al-Hetty, Hussein Riyadh Abdul
AU - Aswood, Murtadha Sh
AU - Turki Jalil, Abduladheem
AU - Azeez, Maha Dhurgham
AU - Aminov, Zafar
AU - Alsaikhan, Fahad
AU - Ramírez-Coronel, Andrés Alexis
AU - Ramaiah, Pushpamala
AU - Farhood, Bagher
N1 - Publisher Copyright:
Copyright © 2023 Gupta, Kareem Al-Hetty, Aswood, Turki Jalil, Azeez, Aminov, Alsaikhan, Ramírez-Coronel, Ramaiah and Farhood.
PY - 2023
Y1 - 2023
N2 - Cancer is caused by defects in coding and non-coding RNAs. In addition, duplicated biological pathways diminish the efficacy of mono target cancer drugs. MicroRNAs (miRNAs) are short, endogenous, non-coding RNAs that regulate many target genes and play a crucial role in physiological processes such as cell division, differentiation, cell cycle, proliferation, and apoptosis, which are frequently disrupted in diseases such as cancer. MiR-766, one of the most adaptable and highly conserved microRNAs, is notably overexpressed in several diseases, including malignant tumors. Variations in miR-766 expression are linked to various pathological and physiological processes. Additionally, miR-766 promotes therapeutic resistance pathways in various types of tumors. Here, we present and discuss evidence implicating miR-766 in the development of cancer and treatment resistance. In addition, we discuss the potential applications of miR-766 as a therapeutic cancer target, diagnostic biomarker, and prognostic indicator. This may shed light on the development of novel therapeutic strategies for cancer therapy.
AB - Cancer is caused by defects in coding and non-coding RNAs. In addition, duplicated biological pathways diminish the efficacy of mono target cancer drugs. MicroRNAs (miRNAs) are short, endogenous, non-coding RNAs that regulate many target genes and play a crucial role in physiological processes such as cell division, differentiation, cell cycle, proliferation, and apoptosis, which are frequently disrupted in diseases such as cancer. MiR-766, one of the most adaptable and highly conserved microRNAs, is notably overexpressed in several diseases, including malignant tumors. Variations in miR-766 expression are linked to various pathological and physiological processes. Additionally, miR-766 promotes therapeutic resistance pathways in various types of tumors. Here, we present and discuss evidence implicating miR-766 in the development of cancer and treatment resistance. In addition, we discuss the potential applications of miR-766 as a therapeutic cancer target, diagnostic biomarker, and prognostic indicator. This may shed light on the development of novel therapeutic strategies for cancer therapy.
KW - biomarker
KW - cancer
KW - drug resistance
KW - miR-766
KW - microRNA
UR - http://www.scopus.com/inward/record.url?scp=85159879055&partnerID=8YFLogxK
U2 - 10.3389/fonc.2023.1173827
DO - 10.3389/fonc.2023.1173827
M3 - Review article
AN - SCOPUS:85159879055
SN - 2234-943X
VL - 13
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1173827
ER -
